title: microRNA expression profile and differentially-expressed genes in prolactinomas             following bromocriptine treatment.
abstract: Little is known about the function of microRNAs in prolactinomas treated             with bromocriptine. The aim of the study was to explore the microRNAs associated             with bromocriptine-treated prolactinomas. Six prolactinoma samples were selected             according to whether they received bromocriptine treatment or not before microsurgery,             and microRNA expression profiles of bromocriptine-treated and untreated prolactinomas             were screened by the miRCURY LNA Array. The differentially expressed microRNAs             in microarrays were further validated by stem-loop real-time PCR and subjected             to gene ontology analysis and KEGG pathway analysis. In addition, related genes             of microRNAs were analyzed by qRT-PCR in 15 prolactinoma samples. The initial             analysis by microarrays generated a list of 80 upregulated microRNAs and 71 downregulated             microRNAs in treated prolactinomas compared to untreated prolactinomas. miR-206,             miR-516b and miR-550 were confirmed to be significantly upregulated, while miR-671-5p             was confirmed to be significantly downregulated in treated prolactinomas by qRT-PCR.             microRNA-mRNA network analysis integrating GO and KEGG pathway annotation displayed             some critical factors. Platelet-derived growth factor α polypeptide (PDGFA) and             bone morphogenetic protein 4 (BMP4), were verified to be differentially expressed             between the two groups. PDGFA was significantly upregulated in treated prolactinomas,             while BMP4 was significantly downregulated in treated prolactinomas. Our study             reveals differential expression of microRNAs in prolactinoma after pharmacotherapy.             Specific microRNAs may be involved in the inhibition or promotion of prolactinoma             tumor growth impacted by bromocriptine pharmacotherapy. PDGFA and BMP4 may be             involved in the pharmacotherapy mechanism of prolactinoma.
authors.affiliation: Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, PR China.
authors.forename: Chengde
authors.initials: C
authors.lastname: Wang
authors.forename: Zhipeng
authors.initials: Z
authors.lastname: Su
authors.forename: Nader
authors.initials: N
authors.lastname: Sanai
authors.forename: Xiangyang
authors.initials: X
authors.lastname: Xue
authors.forename: Lijun
authors.initials: L
authors.lastname: Lu
authors.forename: Yunxiang
authors.initials: Y
authors.lastname: Chen
authors.forename: Jinsen
authors.initials: J
authors.lastname: Wu
authors.forename: Weiming
authors.initials: W
authors.lastname: Zheng
authors.forename: Qichuan
authors.initials: Q
authors.lastname: Zhuge
authors.forename: Zhe Bao
authors.initials: ZB
authors.lastname: Wu
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D016000:Cluster Analysis; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D053263:Gene Regulatory Networks / Q000187:drug effects; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000235:genetics*; D015175:Prolactinoma / Q000188:drug therapy / Q000235:genetics*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D035683:MicroRNAs; D001971:Bromocriptine